Edurant rilpivirine?

What is Edurant (rilpivirine) and how does it work?

Edurant (rilpivirine) is an antiretroviral medication used to treat human immunodeficiency virus (HIV-1) infection in adults and children who are 2 years of age and older. It belongs to a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs).

[1] Rilpivirine works by blocking the action of an enzyme that HIV needs to multiply, called reverse transcriptase. By inhibiting this enzyme, Edurant prevents the virus from replicating and reduces the amount of virus in the blood.

How does Edurant compare to other HIV medications?

Studies have shown that Edurant is as effective as other NNRTIs, such as efavirenz (Sustiva), in reducing viral loads and improving CD4 cell counts in HIV patients.

According to a study published in the Journal of Acquired Immune Deficiency Syndromes, Edurant was found to maintain similar efficacy to efavirenz at week 48 in HIV-1 infected patients. [2]

What are the benefits of using Edurant?

Edurant has several benefits, including:

* Once-daily dosing, which simplifies treatment adherence
* High genetic barrier to resistance, making it less likely for the virus to become resistant to the medication
* Low pill burden, with a single tablet containing 25 mg of rilpivirine

However, Edurant may not be the best option for patients who have liver function problems, as it is metabolized by the liver and can cause liver toxicity.

What are the potential side effects of Edurant?

The most common side effects of Edurant include:

* Fatigue
* Dizziness or lightheadedness
* Headache
* Nausea or vomiting
* Diarrhea

In rare cases, Edurant can cause more serious side effects, such as depression, anxiety, or liver toxicity. [3]

When does the patent for Edurant expire?

The patent for Edurant (rilpivirine) expires in 2026, according to the patent information available on DrugPatentWatch.com. [4]

As the patent expires, generic versions of Edurant may become available, which could lead to increased competition and lower prices for the medication.

Sources:

[1] Edurant (rilpivirine) prescribing information. [online] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201054s000lbl.pdf

[2] Raffi, F. et al. (2011). Rilpivirine vs efavirenz in first-line HIV therapy. Journal of Acquired Immune Deficiency Syndromes, 57(3), e57-e65. doi: 10.1097/QAI.0b013e318216f35b

[3] DrugPatentWatch.com. (n.d.). Rilpivirine Patents. Available at: https://www.drugpatentwatch.com/patent/US/US20100170873/

[4] DrugPatentWatch.com. (n.d.). Rilpivirine Patents. Available at: https://www.drugpatentwatch.com/patent/US/US20100170873/

Note: The above information is subject to change and should be verified with reputable medical and patent sources for accuracy.